ANDA 90505, held by Impax Labs Inc. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 90505 (Doxycycline Hyclate), held by Impax Labs Inc, was first approved by FDA on Dec 28, 2010, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 28, 2010 | Original application | Approved |
| Doxycycline HyclateEQ 75MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Discontinued |
| Doxycycline HyclateEQ 100MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Discontinued |
| Apr 9, 2026 | Supplement 11Labeling · Standard review | Approved | None posted |
| Apr 9, 2026 | Supplement 10Labeling · Standard review | Approved | None posted |
| Apr 9, 2026 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 9, 2026 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 30, 2011 | Supplement 2Labeling | Approved | None posted |
| Nov 30, 2011 | Supplement 1Labeling | Approved | None posted |
| Dec 28, 2010 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters